J. D. Baumgartner - Concepedia

Author

J. D. Baumgartner

Also Known As

J Baumgartner, J D Baumgartner, J. Baumgartner, J. Baumgärtner, J. D. BAUMGARTNER, J. D. Baumgartner, J.-D. Baumgartner, J.D. Baumgartner, Jared Baumgartner

Publications

3.2K

Citations

H-Index

Concepts

All Affiliations

University Hospital of Lausanne Roche (Switzerland)University of California San Diego Hôpital Orthopédique de la Suisse Romande

About

J. D. Baumgartner is an author at University Hospital of Lausanne specializing in medicine, sepsis, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	15	1.4K
2	Health Sciences	5	5	365
3	Allergy	2	2	172
4	Biochemistry	1	1	40
5	Critical Care Medicine	1	1	23

J. D. Baumgartner

Publications

2.2K

Citations

H-Index

Page 1

	Year	Citations
Prognostic Values of Tumor Necrosis Factor/Cachectin, Interleukin-l, Interferon- , and Interferon- in the Serum of Patients with Septic Shock Thierry Calandra, J. D. Baumgartner, Georges E. Grau, The Journal of Infectious Diseases InflammationCytokinePrognostic BiomarkersImmunoreactive TnfMedicine	1990	552
Cytokine production after intravenous or peritoneal gram-negative bacterial challenge in mice. Comparative protective efficacy of antibodies to tumor necrosis factor-alpha and to lipopolysaccharide Gláucia Zanetti, Didier Heumann, J. Gérain, The Journal of Immunology	1992	247
Control of lipopolysaccharide (LPS) binding and LPS-induced tumor necrosis factor secretion in human peripheral blood monocytes Didier Heumann, Philippe Gallay, C Barras, The Journal of Immunology	1992	213
Prospective randomized comparison of imipenem monotherapy with imipenem plus netilmicin for treatment of severe infections in nonneutropenic patients Alain Cometta, J. D. Baumgartner, Daniel Lew, Antimicrobial Agents and Chemotherapy Severe InfectionsHealth SciencesAntibioticsClinical Infectious DiseaseKlebsiella Pneumoniae	1994	204
Association between protective efficacy of anti-lipopolysaccharide (LPS) antibodies and suppression of LPS-induced tumor necrosis factor alpha and interleukin 6. Comparison of O side chain-specific antibodies with core LPS antibodies. J. D. Baumgartner, Didier Heumann, J. Gérain, The Journal of Experimental Medicine Core LpsLaboratory ImmunologyImmunologyImmune RegulationImmunotherapy	1990	150
Short time exposure to lipopolysaccharide is sufficient to activate human monocytes Philippe Gallay, C. Victor Jongeneel, C Barras, The Journal of Immunology	1993	111
IFN-gamma involvement in the severity of gram-negative infections in mice. J Kohler, Didier Heumann, Gianni Garotta, The Journal of Immunology Bolus InjectionsMicrobial PathogensInnate Immune SystemImmunologyInnate Immunity	1993	99
Treatment of severe infectious purpura in children with human plasma from donors immunized with Escherichia coli J5: a prospective double-blind study. J5 study Group. Éric Girardin, J. D. Baumgartner, François Beaufils, SERVAL (Université de Lausanne) Anti-j5 PlasmaEscherichia Coli J5HematologyInflammatory MarkerSepsis	1992	80
Competition between Bactericidal/Permeability-Increasing Protein and Lipopolysaccharide-Binding Protein for Lipopolysaccharide Binding to Monocytes Didier Heumann, Philippe Gallay, S Betz-Corradin, The Journal of Infectious Diseases	1993	71
An extreme form of the hyperdynamic syndrome in septic shock J. D. Baumgartner, Claude Vaney, Cyril Perret Intensive Care Medicine Cardiogenic ShockExtreme FormSepsisMedicineCritical Emergency Medicine	1984	61

Page 1